Patents by Inventor William D.O. Hamilton

William D.O. Hamilton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230646
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 29, 2021
    Inventors: Joergen HANSEN, Esben Halkjaer HANSEN, Honey POLUR, Joseph M. SHERIDAN, Jonathan R. HEAL, William D.O. HAMILTON
  • Patent number: 11008592
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: May 18, 2021
    Assignees: INTERNATIONAL FLAVORS & FRAGRANCES INC., EVOLVA SA
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton
  • Patent number: 10815230
    Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: October 27, 2020
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Ian H. Pike, Karsten Kuhn, Stefan Kienle, William D. O. Hamilton, Jonathan R. Heal, Joseph M. Sheridan
  • Publication number: 20190136270
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 9, 2019
    Inventors: Joergen HANSEN, Esben Halkjaer HANSEN, Honey POLUR, Joseph M. SHERIDAN, Jonathan R. HEAL, William D.O. HAMILTON
  • Patent number: 10208293
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 19, 2019
    Assignees: International Flavors & Fragrances Inc., Evolva SA
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton
  • Publication number: 20180186786
    Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.
    Type: Application
    Filed: May 13, 2016
    Publication date: July 5, 2018
    Applicant: ELECTROPHORETICS LIMITED
    Inventors: Ian H. Pike, Karsten Kuhn, Stefan Kienle, William D.O. Hamilton, Jonathan R. Heal, Joseph M. Sheridan
  • Patent number: 9789111
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: October 17, 2017
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton, Ian H. Pike
  • Patent number: 9763947
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 19, 2017
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton, Ian H. Pike
  • Publication number: 20160354375
    Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 8, 2016
    Applicant: Electrophoretics Limited
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian Pike
  • Publication number: 20160058745
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: September 1, 2015
    Publication date: March 3, 2016
    Applicant: Electrophoretics Limited
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian H. Pike
  • Publication number: 20150209368
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: April 2, 2015
    Publication date: July 30, 2015
    Applicant: Electrophoretics Limited
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian H. Pike
  • Publication number: 20140245496
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: August 7, 2012
    Publication date: August 28, 2014
    Applicants: EVOLVA SA, INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton
  • Publication number: 20140031547
    Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: December 14, 2011
    Publication date: January 30, 2014
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian Pike
  • Publication number: 20140018540
    Abstract: The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1?) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: December 14, 2011
    Publication date: January 16, 2014
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian Pike
  • Patent number: 7879338
    Abstract: The present invention relates to a synthetic plant-optimized nucleic acid molecule having a Norwalk virus capsid protein coding nucleotide sequence, and nucleic acid constructs, host cells, expression systems, and plants having the plant-optimized Norwalk virus nucleic acid molecule. The present invention also relates to a method of producing Norwalk virus capsid protein virus-like particles in a transgenic plant or transgenic plant seed transformed with a plant-optimized nucleic acid molecule encoding Norwalk virus capsid protein. The plant or a component thereof can be administered to a subject under conditions effective to immunize the subject against disease resulting from infection by a Norovirus, including Norwalk virus. An oral vaccine for immunization of a subject against Norwalk virus infection is also disclosed.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: February 1, 2011
    Assignee: Boyce Thompson Institute for Plant Research
    Inventors: William D.O. Hamilton, Koen Hellendoorn, Timothy D. Jones, Dwayne D. Kirk, Hugh S. Mason, Xiuren Zhang, Charles J. Arntzen